UNASSIGNED: 5025 Background: Standard treatment for @entity43 currently consists of surgery followed by chemotherapy. Consolidation may improve survival outcomes by prolonging the disease-free interval. We evaluated a consolidation regimen with weekly @entity1311 infusion and determined the impact on progression-free survival (PFS). METHODS: All @entity1 with @entity43 , treated with @entity1311 consolidation therapy from November 1997 to March 2002, were identified. Consolidation therapy consisted of treatment administered immediately following front-line chemotherapy to @entity1 with no clinical evidence of disease. Treatment consisted of weekly @entity1311 infused at a median dose of 80mg/m(2) (60-80 mg/m(2)) for a maximum of 12 weeks. A chart review was performed to assess the disease status and chemotherapy-related @entity137 in all @entity1 . RESULTS: Thirty-three @entity1 received @entity1311 consolidation therapy over the study period (31 stage III, and 2 stage IV). Twenty-six @entity1 had @entity43 and seven were diagnosed with @entity298 . The overall 2-year survival in this study was 85%: 18 @entity1 (64%) were without evidence of disease and 10 (36%) were alive with disease. The median PFS was 23 months from the date of diagnosis (range: 10-54 months), with a median time to progression of 19 months (range: 10-53 months). The median follow-up was 33 months (range: 16-72 months). During a total of 430 weeks of consolidation therapy, 1 @entity1 experienced Grade 3 @entity16 and 1 @entity1 developed Grade 3 @entity1398 . CONCLUSION: Consolidation therapy with weekly @entity1311 infusion is a well-tolerated regimen that resulted in a median PFS of 23 months in @entity1 who obtained a complete clinical response following induction therapy. Given the lack of side effects and the potential for extending the progression-free survival of those treated, this regimen should be considered when consolidation is planned. No significant financial relationships to disclose.

Consolidation therapy with weekly @entity1311 infusion in XXXX : An extended follow-up.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'advanced epithelial ovarian or primary peritoneal carcinoma', 'epithelial ovarian carcinoma'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity298 :: ('MESH:D010538', 'Disease') :: ['primary peritoneal carcinoma']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
